Consensus Considerations and Good Practice Points for Use of Continuous Glucose Monitoring Systems in Hospital Settings.
Shaw JL, Bannuru RR, Beach L et al.
Diabetes Care. 2024.
https://doi.org/10.2337/dci24-0073
De‐intensification of basal‐bolus therapy by replacing prandial insulin with once‐weekly subcutaneous semaglutide in individuals with well‐controlled type 2 diabetes: A single‐centre, open‐label randomised trial (TRANSITION‐T2D).
Rodriguez P, Breslaw N, Xiao H et al.
Diabetes Obes Metab. 2024.
https://doi.org/10.1111/dom.16057
EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD).
Tacke F, Horn P, Wai-Sun Wong V et al.
J Hepatol. 2024 Sep;81(3):492-542.
https://doi.org/10.1016/j.jhep.2024.04.031
High frequency of severe hyperglycemia observed during intensive hematological care: a prospective study using continuous glucose monitoring.
Tienstra M, de Boer JW, van Doesum JA et al.
Endocr Pract. 2024.
https://doi.org/10.1016/j.eprac.2024.09.013
Islet autoantibody frequency in relatives of children with type 1 diabetes who have a type 2 diabetes diagnosis.
Lewis SJ, Williams CL, Mortimer GL et al.
Diabet Med. 2024.
https://doi.org/doi:10.1111/dme.15394
Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity.
Drucker DJ.
Diabetes Care. 2024 Jun 6:dci240003.
doi:10.2337/dci24-0003
Comentarios recientes